tetano
Editor, Senior Moderator
Clin Transplant
. 2024 Nov;38(11):e15482.
doi: 10.1111/ctr.15482. Lessons Learned From Extracorporeal Life Support Practice and Outcomes During the COVID-19 Pandemic
George Gill[SUP] 1 [/SUP], Michael O'Connor[SUP] 2 [/SUP], Mark E Nunnally[SUP] 3 [/SUP], Alain Combes[SUP] 4 [/SUP], Michael Harper[SUP] 5 [/SUP], David Baran[SUP] 6 [/SUP], Mary Avila[SUP] 7 [/SUP], Barbara Pisani[SUP] 8 [/SUP], Hannah Copeland[SUP] 9 [/SUP], Michael Nurok[SUP] 1 [/SUP]
Affiliations
Extracorporeal membrane oxygenation is increasingly being used to support patients with hypoxemic respiratory failure and cardiogenic shock. During the COVID-19 pandemic, consensus guidance recommended extracorporeal life support for patients with COVID-19-related cardiopulmonary disease refractory to optimal conventional therapy, prompting a substantial expansion in the use of this support modality. Extracorporeal membrane oxygenation was particularly integral to the bridging of COVID-19 patients to heart or lung transplantation. Limited human and physical resources precluded widespread utilization of mechanical support during the COVID-19 pandemic, necessitating careful patient selection and optimal management by expert healthcare teams for judicious extracorporeal membrane oxygenation use. This review outlines the evidence supporting the use of extracorporeal life support in COVID-19, describes the practice and outcomes of extracorporeal membrane oxygenation for COVID-19-related respiratory failure and cardiogenic shock, and proposes lessons learned for the implementation of extracorporeal membrane oxygenation as a bridge to transplantation in future public health emergencies.
Keywords: extracorporeal membrane oxygenation (ECMO); heart disease: infectious; lung disease: infectious.
. 2024 Nov;38(11):e15482.
doi: 10.1111/ctr.15482. Lessons Learned From Extracorporeal Life Support Practice and Outcomes During the COVID-19 Pandemic
George Gill[SUP] 1 [/SUP], Michael O'Connor[SUP] 2 [/SUP], Mark E Nunnally[SUP] 3 [/SUP], Alain Combes[SUP] 4 [/SUP], Michael Harper[SUP] 5 [/SUP], David Baran[SUP] 6 [/SUP], Mary Avila[SUP] 7 [/SUP], Barbara Pisani[SUP] 8 [/SUP], Hannah Copeland[SUP] 9 [/SUP], Michael Nurok[SUP] 1 [/SUP]
Affiliations
- PMID: 39469754
- DOI: 10.1111/ctr.15482
Extracorporeal membrane oxygenation is increasingly being used to support patients with hypoxemic respiratory failure and cardiogenic shock. During the COVID-19 pandemic, consensus guidance recommended extracorporeal life support for patients with COVID-19-related cardiopulmonary disease refractory to optimal conventional therapy, prompting a substantial expansion in the use of this support modality. Extracorporeal membrane oxygenation was particularly integral to the bridging of COVID-19 patients to heart or lung transplantation. Limited human and physical resources precluded widespread utilization of mechanical support during the COVID-19 pandemic, necessitating careful patient selection and optimal management by expert healthcare teams for judicious extracorporeal membrane oxygenation use. This review outlines the evidence supporting the use of extracorporeal life support in COVID-19, describes the practice and outcomes of extracorporeal membrane oxygenation for COVID-19-related respiratory failure and cardiogenic shock, and proposes lessons learned for the implementation of extracorporeal membrane oxygenation as a bridge to transplantation in future public health emergencies.
Keywords: extracorporeal membrane oxygenation (ECMO); heart disease: infectious; lung disease: infectious.